Italian university hospital contributing clinical trial sites, patient cohorts, and decision support expertise in hepatitis B and oncology research.
Azienda Ospedaliero-Universitaria di Parma is a university hospital in Parma, Italy, combining clinical care with academic research. Their H2020 work centers on clinical trials and patient-facing research, particularly in hepatitis B treatment and head-and-neck cancer decision support. They contribute clinical cohorts, patient recruitment capacity, and real-world hospital data to European research consortia. Their strength lies in bridging laboratory science and bedside application within a functioning hospital environment.
TherVacB (therapeutic vaccine trial) and IP-cure-B (immune-based HBV cure) both focus on hepatitis B treatment, with AOP contributing patient cohorts and clinical trial infrastructure.
BD2Decide developed predictive models and decision support systems for personalized head and neck cancer treatment, coordinated by AOP.
EU-CaRE studied the effectiveness and sustainability of cardiac rehabilitation programmes across Europe.
TherVacB involves therapeutic vaccine and adjuvant development for hepatitis B cure, with AOP handling patient stratification and recruitment.
AOP's early H2020 work (2015–2019) focused on data-driven clinical decision support — predictive models and DSS tools for oral cancer — alongside cardiac rehabilitation effectiveness studies. From 2020 onward, the focus shifted decisively toward infectious disease, specifically hepatitis B cure research through therapeutic vaccines, immune therapy, and large-scale clinical trials. This pivot from cancer informatics to virology/immunology clinical trials represents a significant thematic shift within their clinical research portfolio.
AOP is consolidating around hepatitis B clinical research and therapeutic vaccine trials, making them a strong partner for any consortium needing European clinical trial sites in virology.
AOP operates flexibly — they have coordinated one project (BD2Decide), participated as a full partner in two others, and served as a third party in one. With 56 unique partners across 14 countries from just 4 projects, they plug into large international consortia rather than leading them. This profile suggests a reliable clinical partner that provides hospital-based research infrastructure and patient access to broader European teams.
AOP has worked with 56 distinct partners across 14 countries through only 4 projects, indicating participation in large, geographically diverse consortia. Their network spans well beyond Italy, reflecting the international nature of clinical trial collaborations.
As a university hospital, AOP offers something pure research institutes cannot: direct access to patient cohorts, clinical trial infrastructure, and real-world treatment data within an active healthcare setting. Their dual track record in both cancer informatics (as coordinator) and infectious disease trials (as clinical partner) shows versatility across therapeutic areas. For consortium builders, they represent a proven Italian clinical site with experience managing patient recruitment and stratification in multi-country studies.
